Bionano Genomics financials
$1.73+2.98%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $28.5M | $30.8M | $36.1M | $27.8M | $18.0M | $8.5M | $10.1M | $12.0M |
| Gross profit | $13.2M | $380.0K | $9.6M | $5.9M | $3.9M | $2.8M | $3.4M | $3.3M |
| Gross margin | 46.3% | 1.2% | 26.5% | 21.4% | 21.5% | 32.6% | 33.2% | 27.4% |
| Operating income | -$33.3M | -$104.0M | -$215.2M | -$131.7M | -$77.1M | -$38.6M | -$25.9M | -$20.4M |
| Net income | -$26.4M | -$112.0M | -$232.5M | -$132.6M | -$72.4M | -$41.1M | -$29.8M | -$18.5M |
| Net margin | −92.6% | −364.0% | −643.7% | −476.9% | −402.8% | −483.4% | −294.3% | −154.1% |
| Diluted EPS | $-4.85 | $-88.13 | $-408.60 | $-274.80 | $-156.00 | $-234.00 | $-1194.00 | $-1566.00 |
| EBITDA | -$23.8M | -$62.3M | -$123.3M | -$121.9M | -$73.7M | -$37.1M | -$24.7M | -$19.1M |
| Operating cash flow | -$16.3M | -$68.9M | -$125.2M | -$124.8M | -$71.9M | -$38.3M | -$29.4M | -$19.9M |
| Free cash flow | -$16.3M | -$69.0M | -$126.9M | -$128.0M | -$74.0M | -$38.3M | -$29.4M | -$20.3M |
| Diluted shares | 5.4M | 1.3M | 0.6M | 0.5M | 0.5M | 0.2M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.0M | $9.2M | $17.9M | $5.1M | $24.6M | $38.4M |
| Short-term investments | $16.3M | $302.0K | $48.8M | $108.1M | $226.0M | $0.00 |
| Total debt | $13.7M | $24.2M | $73.7M | $3.9M | $3.6M | $16.3M |
| Total assets | $73.6M | $76.7M | $214.4M | $307.5M | $377.1M | $60.5M |
| Total liabilities | $29.2M | $41.3M | $118.2M | $58.1M | $40.0M | $25.4M |
| Shareholders' equity | $44.4M | $35.4M | $96.2M | $249.4M | $337.1M | $35.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology